Ipsen Korea Receives MFDS Director’s Award for Rare‑Disease Patient Support

On the 2nd, Ipsen Korea (CEO Yang Mi‑seon) announced it received the Food and Drug Safety Administration (MFDS) Director’s Award in recognition of its contributions to enhancing safety and treatment access for rare‑disease patients. The award was granted not for a single drug or project but for the company’s long‑term activities aimed at rare‑disease patients and their families, including improving treatment accessibility, raising disease awareness, and providing patient education and support. Ipsen Korea highlighted that over the past 15 years it has focused on the treatment journey of rare‑disease patients, a commitment that was evaluated comprehensively in granting the award.